Cyclized benzamide neurokinin antagonists for use in therapy

Details Cyclized benzamide neurokinin antagonists for use in therapy Cyclized benzamide neurokinin antagonists for use in therapy

2005-08-02

2005-08-02

Kifle, Bruck (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S211050, C514S211060, C514S211070, C540S455000, C540S488000, C540S491000

Reexamination Certificate

active

06924277

ABSTRACT:
Compounds having the general formulawherein R1a, R1b, R1c, X1, X2, R2, R3, R4, R5, R6, n, Y and Z are as defined in the specification, methods of using such compounds for the treatment of diseases and pharmaceutical composition comprising such compounds.

REFERENCES:
patent: 5525600 (1996-06-01), Baudy
patent: 5541179 (1996-07-01), Baudy et al.
patent: 5789422 (1998-08-01), Reichard et al.
patent: 5998439 (1999-12-01), Maynard
patent: WO 9628158 (1996-09-01), None
patent: WO 0064423 (2000-11-01), None
patent: WO 01/77089 (2001-10-01), None
Swain (Ann. Reports Med. Chem.) 1999.
Asianian (Ann. Reports Med. Chem.) 2001.
M. Schuiling et al, ““Role of tachykinin NK1 and NK2 receptors in allergen-induced early and late asthmatic reactions, airway hyperresponsiveness, and airway inflammation in conscious, unrestrained guinea pigs”,” Clinica and Experimental Allergy, p. 48-52.
Marie-Ange Coudore-Civiale et al, ““Effect of tachykinin receptor antagonists in experimental neuropathic pain”,” European Journal of Pharmacology, p. 175-184, (Mar. 14, 1998).
Ludmilla Mazelin et al., ““Comparative effects of nonpeptide tachykinin receptor antagonists on experimental gut inflammation in rats and guinea-pigs”,” Life Sciences, vol. 63 (No. 4), p. 293-304, (Mar. 14, 1998).
D.M. Walsh et al., ““The anxiolytic-like activity of GR159897, a non-peptide NK2 receptor antagonist, in rodent and primate models of anxiety”,” Psychopharmacology, p. 186-191, (Mar. 14, 1995).
Raquel M. Teixeira et al., ““Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice”,” European Journal of Pharmacology, p. 7-14, (Mar. 14, 1996).
Sharon C. Stratton et al., ““Anxiolytic activity of tachykinin NK2 receptor antagonists in the mouse light-dark box”,” European Journal of Pharmacology, p. R11-R12.

Affiliated with

Also associated with

Rating

Cyclized benzamide neurokinin antagonists for use in therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyclized benzamide neurokinin antagonists for use in therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclized benzamide neurokinin antagonists for use in therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3453103